Visx
This article was originally published in The Gray Sheet
Executive Summary
Financier Carl Icahn proposes to nominate six directors to the Visx board at the firm's annual shareholder meeting in late May, according to a Dec. 5 13D filing with the Securities and Exchange Commission. Icahn is seeking to convince the ophthalmic excimer laser manufacturer to merge operations with a larger ophthalmic surgical or pharmaceutical company to enhance shareholder value. Visx adopted a poison pill shareholder rights plan earlier this year to thwart a possible hostile takeover bid that takes effect if an individual or company acquires more than 10% of Visx (1"The Gray Sheet" Aug. 7, 2000, p. 19). Icahn has a 9.95% stake